Douglas Pharmaceuticals

Executive Summary

Douglas Pharmaceuticals is a privately held, New Zealand-based pharmaceutical company with over 50 years of experience in developing, manufacturing, and marketing prescription medicines, over-the-counter products, and nutraceuticals. With a workforce of 500–1000 employees and a focus on small molecule therapeutics, the company operates at a commercial stage, supplying both domestic and international markets. While specific financial and pipeline details are not publicly disclosed due to its private status, Douglas Pharmaceuticals has established itself as a key player in the Australasian pharmaceutical landscape, leveraging its vertically integrated manufacturing capabilities and regulatory expertise. The company's diversified product portfolio across prescription, OTC, and nutraceutical segments provides revenue stability, but its lack of transparency on R&D pipeline and growth metrics limits visibility into near-term value drivers.

Upcoming Catalysts (preview)

• Q3 2026New Product Launch or Indication Expansion70% success
• H2 2026Strategic Manufacturing Partnership or Expansion65% success
• Q4 2026Entry into New Geographic Market50% success